Short Bowel Syndrome and Teduglutide Versus Placebo
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This research study was done to see what the effects are of Teduglutide on people with short
bowel syndrome (SBS). Teduglutide is a synthetic medication administered as an injection,
which has shown to increase intestinal blood flow, inhibit gastric secretion, increase growth
of intestinal cells and increase absorption of nutrients. Teduglutide has demonstrated to
decrease Total Parenteral Nutrition (TPN) requirements by 20%. Teduglutide is approved by the
Food and Drug Administration (FDA) for the treatment of adult patients with Short Bowel
Syndrome (SBS) who are dependent on parenteral support.
The primary hypotheses for this study were 1) that Teduglutide significantly increases the
gastric emptying half time of solids when compared to placebo. 2) Teduglutide will
significantly decrease the intestinal permeability and urinary excretion of lactulose when
compared to placebo.